Skip to main content
International Journal of Women's Health logoLink to International Journal of Women's Health
. 2026 Nov 10;18:648762. doi: 10.2147/IJWH.S648762

Burden and Temporal Trends of Female Breast Cancer Attributable to High Fasting Plasma Glucose in China and G20 Countries, 1990-2023: An Analysis of the Global Burden of Disease Study 2023

Jinzhu Zheng 1,*, Zelin Ye 2,*, Shaoxing Chen 3,*, Wanmei Lin 1, Wenshui Chen 1, Hao Li 1, Zhixing Kuang 4,*,✉, Xiong Wu 2,*
PMCID: PMC13769293  PMID: 43034638

Abstract

Objective

This study aimed to characterise the burden, temporal trends and geographical variation of female breast cancer attributable to high fasting plasma glucose (HFPG) in China and G20 countries from 1990 to 2023, and to provide evidence for targeted prevention and control strategies.

Methods

Attributable burden estimates from the Global Burden of Disease Study 2023 (GBD 2023) were used to compare HFPG-attributable female breast cancer mortality and disability-adjusted life-years (DALYs) between China and G20 countries from 1990 to 2023. Joinpoint regression and age-period-cohort (APC) analyses assessed temporal trends in this burden. Spearman’s correlation analysis explored its association with the Socio-demographic index (SDI) gradient, and decomposition analysis quantified the separate contributions of population ageing, population growth, and epidemiological transitions to changes in burden. A Bayesian age-period-cohort (BAPC) model was applied to project these burden estimates for 2024–2038.

Results

From 1990 to 2023, HFPG-attributable breast cancer deaths, as estimated by the GBD comparative risk assessment framework, increased by 111.19% (15,672 additional deaths) across G20 countries, while age-standardised mortality rate (ASMR) and age-standardised DALY rate (ASDR) modestly decreased by 8.33% and 7.54%. In China, attributable deaths rose by 55.18% (1842 additional deaths), with ASMR and ASDR falling sharply by 38.89% and 43.75%. Marked heterogeneity was observed across G20 countries. Both ASMR and ASDR showed a rebound between 2020 and 2023 in China and G20 countries. The SDI exhibited an inverted U-shaped association with ASMR and ASDR. Population growth and ageing were key contributors to rising attributable burden. BAPC projections suggest that the absolute burden will continue to increase over the subsequent 15 years.

Conclusion

Over the past 30 years, the absolute burden of female breast cancer attributed to HFPG in China and G20 countries has shown an upward trend. Based on BAPC projections, this burden may continue to increase over the next 15 years. Given the significant differences in the characteristics of the transnational burden, countries should adopt targeted public health interventions tailored to their national conditions, such as population size, social development level, and healthcare environment, to address this potential trend.

Keywords: high fasting plasma glucose, breast cancer, disease burden, China, G20 countries

Introduction

Cancer control represents a key global public health priority. A specialised review outlines the historical evolution, contemporary landscape and future directions of modern cancer treatment and prevention, providing foundational context for global cancer control efforts.1 The latest global cancer statistics estimate 2.434 million new cases and 693,700 deaths from female breast cancer worldwide in 2024. Ranking second among all malignancies globally, second only to lung cancer, breast cancer is also the leading cause of cancer death in women in numerous countries.2 According to economic modelling estimates, breast cancer generated a global socioeconomic welfare loss of US $2.538 849 trillion in 2021, accounting for 1.65% of the global gross domestic product; projections suggest that its cumulative global economic toll will exceed US $21 trillion over the next three decades.3 These figures underscore the substantial burden imposed by breast cancer among malignancies in women. Both the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) regard population-level primary prevention as the most cost-effective public-health strategy to mitigate breast-cancer-related disease burden, with modifiable metabolic risk factors identified as core intervention targets for current breast cancer control.4,5 Data from the 2023 Global Burden of Disease (GBD) study confirm that high fasting plasma glucose (HFPG) constitutes the third-largest risk factor driving DALY burden attributable to female breast cancer globally, contributing 5.8% (95% UI, 3.9–8.4) of the total burden.6 HFPG is defined as fasting plasma glucose concentrations above the theoretical minimum risk exposure level (TMREL), the threshold of 4.9–5.3 mmol/L used to identify exposed populations.7 This exposure encompasses individuals meeting diagnostic thresholds for diabetes as well as prediabetic individuals with impaired fasting glucose. It constitutes a widely under-recognised yet broadly reaching metabolic exposure. Unlike analyses restricted solely to clinical diabetes, assessments of HFPG-attributable breast cancer burden capture excess cancer risk that emerges during prediabetes, identify a broader pool of at-risk individuals, and therefore carry unique public health value.

Since 1990, the prevalence of HFPG across all age groups worldwide has continued to rise, driving a growing public-health burden attributable to disordered glucose metabolism. According to the latest estimates from the International Diabetes Federation (IDF) 11th Edition of the Diabetes Atlas (2024), a total of 1.12 billion adults aged 20–79 years globally live with prediabetes defined by impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT), corresponding to an overall prevalence of 19.2%. This figure represents a 28.86% increase in only three years, compared with data reported in 2021.8 Elevated body-mass index (BMI), suboptimal dietary patterns and insufficient physical activity stand out as its three major modifiable risk factors.9,10 Cumulative epidemiological observations and mechanistic pre-clinical studies have demonstrated that sustained hyperglycaemia may raise the incidence- and mortality-related risks of breast cancer in women, via pathways including insulin resistance, chronic low-grade inflammation and disrupted sex-hormone homeostasis.10,11 Importantly, this pro-tumour effect may arise in prediabetes and is not confined to individuals with established diabetes.6

Although mechanistic evidence supports the association between HFPG and breast cancer, substantial research gaps remain. Previous GBD-related burden studies have largely been global pooled analyses or single-country studies, with few standardized cross-national comparisons.12,13 Country-level variations in population structure, metabolic risk factor prevalence, and cancer screening and care systems can substantially shape HFPG-attributable breast cancer burden, global aggregate estimates alone are insufficient to inform targeted national prevention strategies.14 As an economic bloc accounting for more than 80% of global economic output and home to over 60% of the global population, the G20 comprises member states spanning diverse socioeconomic development levels. This bloc carries most of the global burden of hyperglycaemia and female cancers, rendering it an ideal sample to explore cross-country heterogeneity in HFPG-attributable breast cancer burden.15–17 Meanwhile, with substantial global economic influence, the G20 possesses collective potential to tackle a host of global challenges spanning health, social, and environmental domains.18 As the G20’s most populous member, China records the largest number of incident female breast cancer cases among G20 economies and bears the highest absolute burden of HFPG-attributable deaths and DALYs, rendering it an informative case for exploring cross-country disparities in HFPG-related breast cancer burden.12,19,20 Breast cancer ranks as the second most common malignancy among Chinese women, yet its mortality rate has declined.21 Against a backdrop of rapid socio-economic transition, China’s national disease control strategy is shifting from prioritizing treatment to prevention, creating a distinctive setting to examine this disease burden.22 Comparative analyses between China and other G20 nations are of substantial public health importance for developing targeted cross-national prevention strategies.

Available epidemiological evidence suggests that HFPG contributes to a substantial burden of breast cancer, with corresponding patterns shifting with population structure and socio-demographic development.12,13 Drawing on the latest GBD 2023 database, this study systematically quantifies the HFPG-attributable burden of female breast cancer in China and G20 countries from 1990 to 2023. It examines long-term temporal patterns in associated deaths and disability-adjusted life-years (DALYs), and projects burden trajectories over the subsequent 15-year period. We report both absolute and age-standardised metrics, which quantify overall burden while adjusting for cross-country differences in population age structure. The findings provide epidemiological evidence to inform population-level glycaemic management and breast cancer prevention across G20 countries. These data can help identify high-risk populations and priority regions to enable locally adapted, integrated metabolic and oncological prevention strategies, fill cross-national evidence gaps for HFPG-attributable breast cancer burden, and serve as a reference for prevention efforts in regions with comparable burden profiles.

Materials and Methods

Data Sources

Data for disease-burden estimates in this study were derived from the GBD 2023 database. Led by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, this database represents a collaborative effort involving more than 17,000 researchers across over 100 countries and territories, that provides harmonised population-level health-loss estimates for 375 diseases and injuries and 88 risk factors covering 204 countries and territories together with 660 subnational locations from 1990 to 2023.7 And this study incorporated a total of 55,761 independent data sources from diverse health surveillance and research systems.23 All raw input data underwent standardised cleaning, consistency checks, and quality-control filtering; after excluding records with logical inconsistencies, substantial missing values, or evident bias, standard analytical tools such as the Cause of Death Ensemble model (CODEm), Disease Meta-Regression 2.1 (DisMod-MR 2.1), and the comparative risk-assessment framework were applied to generate unified estimates.7,23 Stratified outputs of mortality, incidence, and disability burden metrics were produced by age, sex, and geographic location. Compared with GBD 2021, this update incorporated additional registration datasets, including 312 country-years of vital registration mortality data and 51 country-years of verbal-autopsy data. This update further refined algorithms for misclassification correction of COVID-19-related deaths and optimised the CODEm model to improve the accuracy of cause-specific mortality estimations.20,24

Metrics for HFPG-attributable female breast cancer for individual G20 member states included in this study were extracted via the visualisation portal of the Global Health Data Exchange (GHDx;https://vizhub.healthdata.org/gbd-results/). Data retrieved covered mortality rates, DALYs, as well as their corresponding 95% uncertainty intervals (95% UI). For each indicator, the 95% UI was derived from the 2.5th and 97.5th percentiles of 250 draws from the metric’s distribution to quantify uncertainty in estimates.23 Statistical analyses were performed with stratification by 5-year age groups. As a secondary analysis drawing upon the publicly available GBD 2023 dataset, this study fully complied with data-use policies released by the IHME.

Definitions

Exposure to HFPG was defined using the comparative risk assessment framework of the GBD 2023.7 Among adult women aged 25 years and older, HFPG exposure was identified when fasting plasma glucose (FPG) concentrations exceeded the TMREL range of 4.9–5.3 mmol/L. We included all women with subclinical hyperglycaemia and diabetes with excess risk of breast cancer to quantify the burden of female breast cancer attributable to HFPG.

The analysis covered all 20 G20 members, comprising 19 sovereign states and the European Union (EU), a formal member of the forum. Aggregate disease burden estimates for the G20 and the EU were derived from GBD 2023 summary datasets for the locations “G20” and “European Union”, respectively. The GBD “G20” summary, a precomputed estimate from IHME, avoided double-counting EU member states.

Spearman’s Correlation Analysis

The SDI, which integrates three indicators — fertility rate among people younger than 25 years, mean educational attainment among individuals aged 15 years and older, and per-capita income — quantifies the socioeconomic development status of a given region.25 In this study, Spearman’s correlation coefficient (ρ) was used to assess country-level ecological associations between SDI and both ASMR and ASDR of HFPG-attributable female breast cancer, across individual G20 member states and the G20 aggregate, to characterise cross-national distributional patterns of HFPG-attributable breast cancer burden by socio-demographic development.

Joinpoint Regression Analysis

The Joinpoint regression model (version 5.1.0) was employed in this study to analyze long-term temporal trends in ASMR and ASDR for female breast cancer attributable to HFPG across China and G20 countries from 1990 to 2023. Model parameters were iteratively optimized via the Grid Search Method (GSM) to minimize the overall mean-squared error, and model validity was verified using Monte-Carlo permutation tests, with a maximum of five joinpoints permitted in the analysis.26,27 After natural-log transformation of period-specific indicators, we estimated the annual percentage change (APC) together with its 95% confidence interval for each segment, as well as the overall average annual percentage change (AAPC) spanning 1990 to 2023. APC<0 indicated a downward trend, whereas APC>0 signified an upward trend; AAPC reflected the overall average rate of change in disease burden over the study period. AAPC values were used for cross-country comparison of temporal trends in relevant disease burden among G20 countries over the past three decades.

Age-Period-Cohort (APC) Model

The age-period-cohort (APC) model decomposes temporal trends into age, period, and birth-cohort effects to assess their independent effects on mortality and DALYs of female breast cancer attributable to HFPG.28 Parameter estimates were obtained using the web-based Age-Period-Cohort tool developed by the US National Cancer Institute (https://analysistools.cancer.gov/apc/).29 For this study, age was grouped into 15 five-year age groups, ranging from 25–29 years to 95+ years. Given the data structure constraints of the APC model, the 1990–1993 observation period was excluded to ensure adequate sample size within each age-period-cohort cell and obtain stable parameter estimates. The observation period was divided into six 5-year intervals: 1994–1998, 1999–2003, 2004–2008, 2009–2013, 2014–2018, and 2019–2023. Birth cohorts, partitioned into 20 groups at 10-year intervals, covered individuals born between 1894–1903 and 1989–1998. The mid-period observation window (2004–2008) and the median birth cohort (1939–1948) were selected as reference benchmarks. Net drift characterizes the pooled log-linear long-term temporal trend across all age groups in the total population, whereas local drift reflects the independent log-linear temporal trend within a single age group. All APC statistical analyses were performed in R software (version 4.4.2).

Decomposition Analysis

Das Gupta’s decomposition method was applied to quantify the independent contributions of population ageing, population-level epidemiological changes, and population growth to shifts in HFPG-attributable female breast cancer burden between 1990 and 2023. Multiple counterfactual scenarios were generated, in which two factors were held constant to estimate the independent effect of a single factor. Estimates of each factor’s contribution and their 95% uncertainty intervals were calculated from the 250 posterior samples of the GBD study.30 Comparisons of attributable burden magnitudes provide evidence to inform targeted public health strategies for the prevention and control of HFPG-attributable female breast cancer.

Bayesian Age-Period-Cohort (BAPC) Projection

The BAPC model was applied to project HFPG-attributable female breast cancer burden, including absolute death and DALY counts as well as age-standardised rates, over the subsequent 15 years. This Bayesian age-period-cohort model was fitted to historical age-standardised rates and baseline demographic data, with parameters estimated using the integrated nested Laplace approximation (INLA) algorithm. Gaussian priors were specified for age, period and cohort parameters. Leave-one-out cross-validation was implemented to evaluate predictive performance. Posterior medians and 95% credible intervals were generated to quantify predictive uncertainty. Since epidemiological rate estimates are non-negative, the lower bounds of credible intervals were truncated at zero, while point estimates and upper bounds were retained.31,32

Results

Disease Burden

Over the 34-year timeframe spanning 1990 to 2023, the absolute burden of female breast cancer attributable to elevated HFPG nearly doubled across the G20. Attributable deaths rose from 14,094 to 29,766, corresponding to an 111.19% increase, while DALYs climbed from 415,740 to 821,758, marking a 97.66% increase. After population-based adjustment, only modest declines of 8.33% and 7.54% were observed in the ASMR and ASDR, as shown in Table 1. While G20 countries shared generally comparable temporal trends in standardized mortality and DALY-related risk, countries with higher baseline risk tended to bear heavier disability burdens. Most developed nations, despite elevated initial standardized burden, experienced varying degrees of burden reduction over the study period. Substantial cross-country heterogeneity was observed in long-term burden trajectories: the United Kingdom recorded a sustained sharp drop in standardized burden indicators, China witnessed a mild downward trend, burden indicators in Saudi Arabia, South Africa and several other countries rebounded markedly after 2005, and the rest of member states maintained relatively stable burden levels. In contrast to the pooled G20 profile, China exhibited a modest increase in absolute disease burden, with attributable deaths and DALYs increasing by 55.18% and 31.23% respectively. Its standardized risk fell substantially, with ASMR and ASDR dropping by 38.89% and 43.75%, placing China’s overall standardized burden among the lower end of the spectrum within G20 countries (Table 1, Figure 1 and Supplementary Figure S1).

Table 1.

Comparison of the Burden of Female Breast Cancer Attributable to HFPG in China and G20 Countries,1990 and 2023

Country/Region Measure 1990 2023
Counts (n (95% UI)) Age-Standardized Rate per 100,000 People (n (95% UI)) Counts (n (95% UI)) Age-Standardized Rate per 100,000 People (n (95% UI))
G20 Deaths 14,094 (8861–22465) 0.96 (0.61–1.53) 29,766 (20560–43464) 0.88 (0.60–1.29)
DALYs 415,740 (252273–680912) 27.71 (16.89–45.21) 821,758 (554508–1205039) 25.62 (17.10–37.93)
China Deaths 3338 (1887–5368) 0.72 (0.41–1.17) 5180 (3589–7745) 0.44 (0.31–0.66)
DALYs 121,262 (66563–192271) 25.10 (13.94–39.97) 159,132 (106458–237314) 14.12 (9.44–21.10)
Argentina Deaths 279 (179–435) 1.57 (1.01–2.45) 483 (330–727) 1.40 (0.92–2.17)
DALYs 7357 (4640–11738) 41.81 (26.25–66.77) 12,192 (7631–19259) 38.53 (23.51–61.80)
Australia Deaths 103 (63–176) 0.96 (0.58–1.63) 259 (162–427) 0.96 (0.59–1.60)
DALYs 2526 (1501–4398) 24.69 (14.72–42.88) 5982 (3637–10234) 25.86 (15.44–44.93)
Brazil Deaths 717 (419–970) 1.46 (0.85–1.97) 2109 (1253–2921) 1.45 (0.86–2.02)
DALYs 23,171 (13264–31763) 43.62 (25.27–59.43) 61,279 (34789–88253) 42.94 (24.24–61.90)
Canada Deaths 223 (143–346) 1.23 (0.78–1.90) 390 (283–542) 0.93 (0.68–1.26)
DALYs 5781 (3583–8982) 33.70 (20.65–52.93) 9021 (6609–12243) 25.18 (18.16–33.41)
European Union Deaths 4557 (3009–7476) 1.31 (0.85–2.18) 6956 (4949–9653) 1.21 (0.88–1.68)
DALYs 113,114 (71786–190855) 35.75 (22.21–61.33) 149,589 (107196–206581) 31.73 (22.18–44.25)
France Deaths 511 (334–777) 1.05 (0.67–1.63) 887 (519–1514) 1.04 (0.58–1.85)
DALYs 12,206 (7679–19309) 29.06 (17.89–47.04) 19,648 (10919–34525) 28.88 (15.39–52.42)
Germany Deaths 1236 (812–1922) 1.58 (1.03–2.46) 1686 (1219–2294) 1.47 (1.07–1.96)
DALYs 28,811 (18508–45283) 41.88 (26.69–66.45) 34,836 (24759–48123) 38.00 (25.23–54.61)
India Deaths 1007 (533–1917) 0.42 (0.22–0.78) 6137 (3276–10463) 0.94 (0.50–1.60)
DALYs 34,778 (18056–69184) 12.85 (6.83–24.87) 190,134 (100185–327337) 27.49 (14.62–47.18)
Indonesia Deaths 225 (122–442) 0.40 (0.21–0.79) 1192 (667–2172) 0.77 (0.44–1.43)
DALYs 7907 (4382–15512) 12.66 (6.93–24.95) 42,659 (23936–77990) 26.26 (14.73–48.24)
Italy Deaths 670 (418–1044) 1.33 (0.81–2.12) 961 (629–1426) 1.08 (0.70–1.60)
DALYs 16,713 (10141–26662) 36.23 (21.44–59.34) 19,407 (12545–28583) 27.51 (17.36–42.51)
Japan Deaths 458 (266–689) 0.50 (0.29–0.76) 1631 (931–2371) 0.82 (0.49–1.22)
DALYs 14,497 (8085–22612) 16.27 (9.00–25.74) 35,370 (21058–52466) 24.38 (14.50–38.24)
Mexico Deaths 229 (152–298) 0.96 (0.65–1.24) 802 (617–1015) 1.07 (0.82–1.35)
DALYs 7580 (4767–10025) 29.39 (19.07–38.28) 25,189 (19183–31545) 32.92 (25.18–41.25)
Korea Deaths 53 (33–94) 0.29 (0.18–0.50) 165 (103–258) 0.32 (0.19–0.51)
DALYs 1928 (1164–3405) 9.74 (5.88–17.37) 4930 (2927–8116) 10.53 (6.17–17.47)
Russian Federation Deaths 740 (402–1437) 0.66 (0.35–1.29) 1397 (810–2259) 0.91 (0.52–1.48)
DALYs 21,827 (11399–43296) 20.29 (10.54–40.53) 36,044 (20079–59858) 25.27 (13.94–42.72)
Saudi Arabia Deaths 15 (8–27) 0.65 (0.37–1.13) 119 (77–175) 1.98 (1.29–2.88)
DALYs 488 (268–890) 17.56 (9.88–31.00) 4013 (2586–6222) 51.82 (33.92–76.70)
South Africa Deaths 87 (52–158) 0.73 (0.44–1.32) 538 (339–755) 1.72 (1.08–2.40)
DALYs 2590 (1514–4868) 20.60 (12.03–38.70) 16,550 (10347–24460) 50.55 (31.45–73.66)
Türkiye Deaths 114 (62–207) 0.62 (0.33–1.12) 538 (321–780) 1.00 (0.60–1.45)
DALYs 3651 (1987–6640) 18.25 (9.92–33.05) 16,124 (9366–24779) 30.19 (17.53–46.55)
United Kingdom Deaths 1404 (812–1996) 2.72 (1.55–4.04) 1432 (1029–1869) 1.86 (1.24–2.47)
DALYs 32,172 (17755–49918) 71.44 (38.49–118.20) 30,775 (19689–41807) 48.23 (28.67–68.21)
United States of America Deaths 2684 (1701–4551) 1.50 (0.94–2.55) 3863 (2412–6062) 1.21 (0.75–1.90)
DALYs 70,497 (43101–122126) 42.92 (25.97–74.49) 98,474 (61326–153855) 34.91 (21.44–54.73)

Abbreviations: HFPG, high fasting plasma glucose; DALYs, disability-adjusted life-years; UI, uncertainty interval.

Figure 1.

A mixed bar and line chart showing deaths and disability adjusted life years for China and the G20 over time. A) Mixed bar and line graph of deaths over time for China and the G20. Text above plot: A. Horizontal axis label: Year. Tick labels shown: 1990, 1995, 2000, 2005, 2010, 2015, 2020. Left vertical axis label: Number of Deaths. Range shown: 0 to 40,000. Right vertical axis label: Age standardized mortality rate per 100,000. Range shown: 0.0 to 4.0. Plotted elements and legends shown below the plot: Legend: G20 Number of deaths; G20 95 percent uncertainty interval for age standardized mortality rate; China Number of deaths; China 95 percent uncertainty interval for age standardized mortality rate. Legend: G20 age standardized mortality rate; China age standardized mortality rate. Bars and uncertainty intervals: G20 Number of deaths is shown as a set of vertical bars increasing across the years. The bar heights start near 14,000 around 1990 and rise gradually through the 1990s and 2000s, reaching around 20,000 by about 2010, then increasing more steeply after about 2015 and reaching close to 30,000 by the final years near 2023. China Number of deaths is shown as a smaller set of vertical bars. The bar heights start near 3,000 to 4,000 around 1990, remain in that general range through the 1990s and 2000s, dip slightly around the mid to late 2000s, then rise again after about 2015, ending near 5,000 by the final years. Vertical uncertainty interval whiskers are drawn above the bars for the G20 series, extending upward to values above 40,000 in the final years. Shaded uncertainty bands are shown for the age standardized mortality rate series for both the G20 and China, labeled as 95 percent uncertainty interval for age standardized mortality rate. Lines: G20 age standardized mortality rate is shown as a line that begins just under 1.0 around 1990, trends downward through the 1990s and 2000s, reaches a low point around the mid 2010s, then turns slightly upward toward the final years. China age standardized mortality rate is shown as a line that begins below the G20 line around 1990, declines more strongly through the 1990s and 2000s, reaches a low point around the mid to late 2010s, then rises slightly toward the final years. B) Mixed bar and line graph of disability adjusted life years over time for China and the G20. Text above plot: B. Horizontal axis label: Year. Tick labels shown: 1990, 1995, 2000, 2005, 2010, 2015, 2020. Left vertical axis label: Number of disability adjusted life years. Range shown: 0 to 1,250,000. Right vertical axis label: Age standardized disability adjusted life year rate per 100,000. Range shown: 0.0 to 125.0. Plotted elements and legends shown below the plot: Legend: G20 disability adjusted life years; G20 95 percent uncertainty interval for age standardized disability adjusted life year rate; China disability adjusted life years; China 95 percent uncertainty interval for age standardized disability adjusted life year rate. Legend: G20 age standardized disability adjusted life year rate; China age standardized disability adjusted life year rate. Bars and uncertainty intervals: G20 disability adjusted life years are shown as vertical bars increasing over time. The bars start around 400,000 to 450,000 near 1990, rise gradually through the 1990s and 2000s to around 550,000 to 600,000 by about 2010, then increase more steeply after about 2015, reaching roughly 800,000 to 850,000 by the final years. China disability adjusted life years are shown as smaller vertical bars. The bars start around 120,000 to 150,000 near 1990, remain near that level through the 1990s and early 2000s, dip slightly around the late 2000s to early 2010s, then rise again after about 2015, ending near 160,000 to 180,000 by the final years. Vertical uncertainty interval whiskers are drawn above the G20 bars, extending upward to values above 1,000,000 in the final years. Shaded uncertainty bands are shown for the age standardized disability adjusted life year rate series for both the G20 and China, labeled as 95 percent uncertainty interval for age standardized disability adjusted life year rate. Lines: G20 age standardized disability adjusted life year rate is shown as a line starting near the mid 20s around 1990, declining gradually through the 1990s and 2000s, reaching a low point around the mid 2010s, then rising slightly toward the final years. China age standardized disability adjusted life year rate is shown as a line starting below the G20 line around 1990, declining more strongly through the 1990s and 2000s, reaching a low point around the mid to late 2010s, then rising slightly toward the final years. A) and B) use the same Year axis and compare the same two groups, China and the G20, with bars for counts and lines for age standardized rates.

Temporal trends in female breast cancer burden attributable to HFPG in China and the G20, 1990–2023. (A) Number of Deaths; ASMR, age-standardized mortality rate; (B) Number of DALYs.

Abbreviations: ASDR, age-standardized DALY rate. DALY, disability-adjusted life year; UI, uncertainty interval.

Age-Stratified Disease-Burden Characteristics

As demonstrated in Figure 2, breast-cancer-specific mortality and DALYs rates remained low among women aged 25–45 years in both China and the G20 in 1990 and 2023. After the age of 45, burden indicators began to diverge, with inter-group gaps widening steadily as age advanced. For mortality outcomes, older women in the G20 experienced a steep age-related increase in breast-cancer-specific mortality; women aged 95 years and older had significantly higher mortality than their age-matched Chinese counterparts. Regarding age-specific DALY metrics, the G20 showed a continuous upward trend with increasing age. In sharp contrast, China’s DALYs burden peaked in middle-and-older-age strata and then decreased among the oldest-old groups. Furthermore, middle-aged and elderly Chinese women experienced a reduction in breast-cancer-attributable disease burden in 2023 relative to 1990. Supplementary Figure S2 revealed that breast-cancer-related deaths across the G20 mainly occurred in women aged 50 years and older, with the mortality peak observed in the 65–69 age group. Geriatric mortality burden showed substantial cross-national heterogeneity. The EU, India, China and the United States accounted for the majority of fatal cases, and China and India bore the largest mortality share in the 55–74 age group. The age-based peak of DALYs burden shifted to the 55–59 age group, and the 50–64 age group incurred the largest cumulative healthy-life-year loss. Despite minimal mortality cases among 25–44-year-old women, considerable disability-related DALYs losses persisted in this young-and-middle-aged subgroup. Compared with data from 1990, overall breast-cancer-related mortality and healthy-life-loss burden increased sharply across the G20 in 2023. China, India and the EU remained the primary contributors to breast-cancer disease burden.

Figure 2.

A multi-line graph set of four plots comparing China and G20 rates across age groups. A) Line graph with two series and shaded bands. Legend text: Region, China, G20. Horizontal axis label: Age Group, unit not shown. Horizontal axis categories: 25 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 plus. Vertical axis label: Age specific mortality rate, unit not shown. Vertical axis tick labels visible: 0, 10, 20. Vertical axis range visible: 0 to 20. Series identification: China line with point markers and a shaded band; G20 line with point markers and a shaded band. Approximate plotted values at readable ticks: G20 at 25 to 29 is near 25 to 29: 0; G20 at 65 to 69 is near 65 to 69: 5; G20 at 80 to 84 is near 80 to 84: 10; G20 at 95 plus is near 95 plus: 18. China at 25 to 29 is near 25 to 29: 0; China at 65 to 69 is near 65 to 69: 3; China at 80 to 84 is near 80 to 84: 3; China at 95 plus is near 95 plus: 3. Trend comparison: both series rise from 25 to 29 through mid ages; G20 rises sharply after 70 to 74 and continues upward to 95 plus, while China stays near a low single digit level from 65 to 69 through 95 plus. B) Line graph with two series and shaded bands. Legend text: Region, China, G20. Horizontal axis label: Age Group, unit not shown. Horizontal axis categories: 25 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 plus. Vertical axis label: Age specific DALY rate, unit not shown. Vertical axis tick labels visible: 0, 50, 100, 150, 200, 250. Vertical axis range visible: 0 to 250. Series identification: China line with point markers and a shaded band; G20 line with point markers and a shaded band. Approximate plotted values at readable ticks: G20 at 25 to 29 is near 25 to 29: 0; G20 at 55 to 59 is near 55 to 59: 100; G20 at 75 to 79 is near 75 to 79: 100; G20 at 95 plus is near 95 plus: 160. China at 25 to 29 is near 25 to 29: 0; China at 55 to 59 is near 55 to 59: 110; China at 65 to 69 is near 65 to 69: 60; China at 95 plus is near 95 plus: 30. Peak and variation: China peaks around 55 to 59 near 110 then declines steadily toward older ages; G20 rises to about 100 by 55 to 59, stays near 100 through 80 to 84, then increases toward 95 plus. C) Line graph with two series and shaded bands. Legend text: Region, China, G20. Horizontal axis label: Age Group, unit not shown. Horizontal axis categories: 25 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 plus. Vertical axis label: Age specific mortality rate, unit not shown. Vertical axis tick labels visible: 0, 10, 20, 30. Vertical axis range visible: 0 to 30. Series identification: China line with point markers and a shaded band; G20 line with point markers and a shaded band. Approximate plotted values at readable ticks: G20 at 25 to 29 is near 25 to 29: 0; G20 at 65 to 69 is near 65 to 69: 5; G20 at 80 to 84 is near 80 to 84: 10; G20 at 95 plus is near 95 plus: 22. China at 25 to 29 is near 25 to 29: 0; China at 65 to 69 is near 65 to 69: 2; China at 80 to 84 is near 80 to 84: 3; China at 95 plus is near 95 plus: 5. Trend comparison: both series increase with age; G20 increases more steeply after 70 to 74 and reaches above 20 by 95 plus, while China remains below 10 through 95 plus. D) Line graph with two series and shaded bands. Legend text: Region, China, G20. Horizontal axis label: Age Group, unit not shown. Horizontal axis categories: 25 to 29, 30 to 34, 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, 60 to 64, 65 to 69, 70 to 74, 75 to 79, 80 to 84, 85 to 89, 90 to 94, 95 plus. Vertical axis label: Age specific DALY rate, unit not shown. Vertical axis tick labels visible: 0, 50, 100, 150, 200, 250. Vertical axis range visible: 0 to 250. Series identification: China line with point markers and a shaded band; G20 line with point markers and a shaded band. Approximate plotted values at readable ticks: G20 at 25 to 29 is near 25 to 29: 0; G20 at 55 to 59 is near 55 to 59: 80; G20 at 80 to 84 is near 80 to 84: 100; G20 at 95 plus is near 95 plus: 180. China at 25 to 29 is near 25 to 29: 0; China at 55 to 59 is near 55 to 59: 60; China at 65 to 69 is near 65 to 69: 70; China at 95 plus is near 95 plus: 60. Peak and variation: G20 rises across age groups and increases sharply after 85 to 89; China rises to around 65 to 69 then stays near the 60 to 70 range through 95 plus.

Age-related disparities in female breast cancer attributable to HFPG in China and the G20. (A) age-specific mortality rate (1990); (B) age-specific DALY rate (1990). DALY, disability-adjusted life year; (C) age-specific mortality rate (2023); (D) age-specific DALY rate (2023).

Joinpoint Regression Analysis

Supplementary Table S1 and Figure 3 showed that ASMR and ASDR for female breast cancer attributable to HFPG showed an overall decreasing trend in China from 1990 to 2023. The AAPC stood at −1.46 (95% CI −1.99 to −0.93, P < 0.05) for ASMR and −1.73 (95% CI −1.98 to −1.48, P < 0.05) for ASDR. The most pronounced reductions occurred in 1997–2014, during which the APC reached −3.01 (95% CI −3.17 to −2.86) for ASMR and −3.48 (95% CI −3.64 to −3.31) for ASDR. Of note, both indicators rebounded substantially during 2020–2023, with an APC of 4.86 (95% CI 2.62 to 7.15) for ASMR and 4.17 (95% CI 2.13 to 6.26) for ASDR.When compared with the G20, declines in ASMR and ASDR were also noted over the 34-year study period, albeit with considerably smaller magnitudes;the AAPC for the G20 was −0.28 (95% CI −0.45 to −0.11, P < 0.05) for ASMR and −0.24 (95% CI −0.37 to −0.11, P < 0.05) for ASDR, with the sharpest decrease occurring from 1995 to 2013. Figure 3C summarises between-country variations in AAPC across individual G20 countries from 1990 to 2023, revealing strong consistency between long-term mortality and DALYs burden trends. Sustained reductions in breast cancer-related burden, as reflected by declining ASMR and ASDR, were found in China, the United Kingdom (UK), Canada, Italy, the United States of America(USA), and the EU; among these regions, China had the largest AAPC reduction. By contrast, Saudi Arabia, South Africa, India, Indonesia, Türkiye, Japan, and Russia showed persistent increases in disease burden, with the largest annual increases observed in Saudi Arabia and South Africa.

Figure 3.

A multi plot figure showing China and G20 trends and country comparisons for ASMR and ASDR. A) Line graph with markers comparing China and G20 over time for ASMR. The x axis label is Year with values from 1990 to 2023. The y axis label is ASMR with unit per 100000. Tick values are 0.4, 0.6, 0.8 and 1.0. A legend titled Country or Region lists China and G20. Joinpoint labels appear on the lines: G20 joinpoint 1995, G20 joinpoint 2013, G20 joinpoint 2017, G20 joinpoint 2020, China joinpoint 1997, China joinpoint 2014, China joinpoint 2017, China joinpoint 2020. A text block lists segment annual percent change values. For China: 1990 to 1997 annual percent change minus 0.567, 1997 to 2014 annual percent change minus 3.0133, 2014 to 2017 annual percent change minus 0.6919, 2017 to 2020 annual percent change minus 2.9272, 2020 to 2023 annual percent change 4.8584. For G20: 1990 to 1995 annual percent change 0.0133, 1995 to 2013 annual percent change minus 1.0152, 2013 to 2017 annual percent change 0.7477, 2017 to 2020 annual percent change minus 0.3262, 2020 to 2023 annual percent change 2.3682. The plotted China series starts near 0.72 at 1990, declines to about 0.70 by 1997, then declines steadily to about 0.45 by 2014, continues down to about 0.42 by 2020, then rises to about 0.45 by 2023. The plotted G20 series starts near 0.97 at 1990, stays near 0.97 through about 1995, declines to about 0.82 by 2013, rises slightly to about 0.83 by 2017, dips slightly to about 0.82 by 2020, then rises to about 0.88 by 2023. B) Line graph with markers comparing China and G20 over time for ASDR. The x axis label is Year with values from 1990 to 2023. The y axis label is ASDR with unit per 100000. Tick values are 15, 20 and 25. A legend titled Country or Region lists China and G20. Joinpoint labels appear on the lines: G20 joinpoint 1996, G20 joinpoint 2006, G20 joinpoint 2013, G20 joinpoint 2016, G20 joinpoint 2020, China joinpoint 1997, China joinpoint 2013, China joinpoint 2020. A text block lists segment annual percent change values. For China: 1990 to 1997 annual percent change minus 0.7550, 1997 to 2013 annual percent change minus 3.4775, 2013 to 2020 annual percent change minus 1.1353, 2020 to 2023 annual percent change 4.1749. For G20: 1990 to 1996 annual percent change 0.0032, 1996 to 2006 annual percent change minus 1.2329, 2006 to 2013 annual percent change minus 0.9567, 2013 to 2016 annual percent change 0.8935, 2016 to 2020 annual percent change 0.0767, 2020 to 2023 annual percent change 2.7679. The plotted China series starts near 25.2 at 1990, declines slightly to about 24.5 by 1997, then declines steeply to about 14.0 by 2013, declines further to about 13.0 by 2020, then rises to about 14.2 by 2023. The plotted G20 series starts near 28.0 at 1990, stays near 28.0 through about 1996, declines to about 24.5 by 2006, declines to about 23.0 by 2013, rises slightly to about 23.5 by 2016, stays near 23.5 through about 2020, then rises to about 25.5 by 2023. C) Two horizontal bar charts comparing AAPC from 1990 to 2023 for G20 countries, one chart labeled ASMR and one chart labeled ASDR. The shared x axis label is AAPC, 1990 to 2023 with unit percent. Tick values are negative 2, 0 and 2. The y axis label is G20 countries, listing from top to bottom: Saudi Arabia, South Africa, India, Indonesia, Turkiye, Japan, Russian Federation, Mexico, Republic of Korea, Australia, France, Brazil, Argentina, Germany, European Union, United States of America, Italy, Canada, United Kingdom, China. Bars represent positive values on the positive side of the axis and negative values on the negative side of the axis, with horizontal error bars showing confidence intervals. A small legend labeled Trend shows Negative and Positive. In the ASMR bar chart, positive bars appear for Saudi Arabia, South Africa, India, Indonesia, Turkiye, Japan, Russian Federation, Mexico, Republic of Korea. Australia and France are near zero. Negative bars appear for Brazil, Argentina, Germany, European Union, United States of America, Italy, Canada, United Kingdom and China, with China extending farthest toward negative 2. In the ASDR bar chart, positive bars appear for Saudi Arabia, South Africa, India, Indonesia, Turkiye, Japan, Russian Federation, Mexico, Republic of Korea and Australia. France is near zero. Negative bars appear for Brazil, Argentina, Germany, European Union, United States of America, Italy, Canada, United Kingdom and China, with China extending farthest toward negative 2. A and B show time series for China and G20 and C summarizes country level AAPC comparisons for ASMR and ASDR.

Joinpoint analysis of age-standardized rates of female breast cancer attributable to HFPG in China and G20 countries, 1990–2023.(A) ASMR; (B) ASDR; (C) AAPC with 95% CI. “*” indicates that the APC is significant (p < 0.05).

Abbreviations: ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; DALY, disability-adjusted life year; APC, annual percent change; AAPC,average annual percent change; CI, confidence interval.

Age-Period-Cohort Analysis

Figure 4 revealed that the mortality rate of female breast cancer attributable to HFPG rose with age in both China and the G20. Mortality remained exceedingly low and nearly identical among women aged 25–54 years. After age 55, however, mortality climbed far more rapidly across the G20 than within China, with this disparity continuing to widen beyond age 75.China’s age-specific DALYs rate exhibited an inverted-V profile, peaking in the 50–54 years old group before declining steeply. By contrast, the G20 DALYs rate followed a three-phase trajectory: initial growth, a plateau phase, and a subsequent rise (Figure 4A). Period-effect analysis demonstrated that mortality has declined over the past 30 years. Before 2008, breast-cancer-related disease burden was higher in China than the aggregate G20 level. After 2008, China’s mortality declined substantially faster than the overall G20 average. A modest rise in mortality risk was observed for both China and the G20 in 2023. Time-series DALYs estimates closely mirrored age-specific mortality trends (Figure 4B). Birth-cohort analyses indicated that mortality rates first increased and then decreased alongside progressively later birth cohorts for both China and the G20. Chinese cohorts born after 1949 experienced sustained, sharp reductions in HFPG-attributable breast cancer mortality; later-born Chinese cohorts presented markedly lower mortality than their G20 counterparts. DALYs trends tracked mortality shifts, albeit with comparatively minor inter-group gaps (Figure 4C). Net drift values for both mortality and DALY rates were <0, signifying reductions in HFPG-attributable female breast-cancer mortality and DALY burden from 1990 to 2023 across China and the G20. Local age-stratified outcomes showed a prominent burden reduction among Chinese women aged 25–74 years, while age-specific burden stayed relatively stable for the G20. Burden rose slightly in the population aged 85 years and older, signalling an age-distribution shift towards older adults (Figure 4D).

Figure 4.

Four-part plots comparing China and G20 deaths and DALYs by age, period, cohort and drift. A) Two line graphs labeled, Deaths and DALYs, comparing China and G20 with shaded 95 percent confidence intervals. X axis label is, Age, with age groups from 25 to 29 through 95 plus. Deaths graph y axis label is, Rate, unit not shown. China increases from near 0 at 25 to 29 to about 3 at 95 plus. G20 increases from near 0 at 25 to 29 to about 18 at 95 plus, with the steepest rise after 75 to 79. DALYs graph y axis label is, Rate, unit not shown. China rises from about 10 at 25 to 29 to a peak near 80 at 50 to 54, then declines to about 30 by 80 to 84 and stays near 30 to 35 through 95 plus. G20 rises from about 5 to 10 at 25 to 29 to about 70 to 80 at 50 to 54, stays near 85 to 90 from 55 to 59 through 80 to 84, then rises to about 150 to 160 at 95 plus. B) Two line graphs labeled, Deaths and DALYs, comparing China and G20 with shaded 95 percent confidence intervals. X axis label is, Period, with categories 1994 to 1998, 1999 to 2003, 2004 to 2008, 2009 to 2013, 2014 to 2018 and 2019 to 2023. Each plot shows a dashed horizontal reference line at 1.0 and a dashed vertical line at 2004 to 2008. Y axis label is, Rate ratio, unit not shown. Deaths: China is about 1.4, 1.2, 1.0, 0.88, 0.83, 0.86 across the six periods. G20 is about 1.1, 1.05, 1.0, 0.97, 0.97, 1.0. DALYs: China is about 1.4, 1.2, 1.0, 0.88, 0.84, 0.90. G20 is about 1.1, 1.05, 1.0, 0.97, 0.98, 1.0. C) Two line graphs labeled, Deaths and DALYs, comparing China and G20 with shaded 95 percent confidence intervals. X axis label is, Cohort, with categories from 1894 to 1898 through 1994 to 1998. Each plot shows a dashed horizontal reference line at 1.0 and a dashed vertical line at 1944 to 1948. Y axis label is, Rate ratio, unit not shown. Deaths: China starts near 1.0, rises slightly above 1.0 in early cohorts, then declines after mid century cohorts, reaching about 0.2 by 1994 to 1998. G20 stays close to 1.0 across cohorts and ends just under 1.0 in later cohorts. DALYs: China is near 1.0 in early cohorts, then declines after about 1944 to 1948 to about 0.2 to 0.3 by 1994 to 1998. G20 remains near 1.0 across cohorts with a small downward shift in later cohorts. D) Two heatmap tables titled, China and G20, with a legend labeled, Value, ranging from 1 to minus 5. X axis label is, Measure, with columns Deaths and DALYs. Y axis label is, Age Group, listing 25 to 29 through 95 plus. A top row labeled, Net Drift percent per year, shows China: Deaths minus 2.13 and DALYs minus 1.93; G20: Deaths minus 0.48 and DALYs minus 0.43. Printed cell values by age group are as follows. China Deaths: 25 to 29 minus 5.34, 30 to 34 minus 4.87, 35 to 39 minus 4.39, 40 to 44 minus 4.16, 45 to 49 minus 3.83, 50 to 54 minus 3.26, 55 to 59 minus 2.66, 60 to 64 minus 2.09, 65 to 69 minus 1.41, 70 to 74 minus 0.96, 75 to 79 minus 0.56, 80 to 84 minus 0.12, 85 to 89 0.29, 90 to 94 0.63, 95 plus 1.09. China DALYs: 25 to 29 minus 5.22, 30 to 34 minus 4.77, 35 to 39 minus 4.29, 40 to 44 minus 4.04, 45 to 49 minus 3.67, 50 to 54 minus 3.07, 55 to 59 minus 2.47, 60 to 64 minus 1.88, 65 to 69 minus 1.15, 70 to 74 minus 0.67, 75 to 79 minus 0.28, 80 to 84 0.14, 85 to 89 0.48, 90 to 94 0.74, 95 plus 1.14. G20 Deaths: 25 to 29 0.54, 30 to 34 0.19, 35 to 39 minus 0.15, 40 to 44 minus 0.53, 45 to 49 minus 0.90, 50 to 54 minus 0.98, 55 to 59 minus 0.84, 60 to 64 minus 0.58, 65 to 69 minus 0.47, 70 to 74 minus 0.47, 75 to 79 minus 0.46, 80 to 84 minus 0.49, 85 to 89 minus 0.38, 90 to 94 minus 0.02, 95 plus 0.36. G20 DALYs: 25 to 29 0.52, 30 to 34 0.16, 35 to 39 minus 0.18, 40 to 44 minus 0.55, 45 to 49 minus 0.90, 50 to 54 minus 0.95, 55 to 59 minus 0.78, 60 to 64 minus 0.50, 65 to 69 minus 0.36, 70 to 74 minus 0.37, 75 to 79 minus 0.39, 80 to 84 minus 0.43, 85 to 89 minus 0.34, 90 to 94 0.02, 95 plus 0.38.

Age, period, and cohort effects on mortality and DALYs of female breast cancer attributable to HFPG in China and the G20. (A) Age effect; (B) Period effect; (C) Cohort effect; (D) Net and local drifts. Shaded regions indicate the 95% confidence intervals.

Abbreviations: DALYs, disability-adjusted life years.

Spearman’s Correlation Analysis with SDI

Spearman’s correlation analysis uncovered positive correlations between the SDI and both HFPG-attributable female breast cancer ASMR (ρ=0.281, p<0.001) and ASDR (ρ=0.214, p<0.001) across the G20 from 1990 to 2023. Based on curve-fitting results, both association curves showed an inverted-U shape: disease burden increased with rising SDI at low-to-moderate SDI levels, before gradually declining at high SDI values. Temporal trajectories differed markedly across countries at different developmental levels, and SDI was more strongly correlated with mortality burden than with disability burden (Figure 5).

Figure 5.

Two scatter plots of Socio-Demographic Index versus female breast cancer burden from HFPG with fitted curves. A) Scatter plot with multiple country trajectories and a smooth fitted curve relating Socio-Demographic Index to 1990 to 2023 age standardized mortality rate per 100,000. The x-axis label is Socio-Demographic Index, with tick labels at 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9. The y-axis label is 1990 to 2023 age standardized mortality rate per 100,000, with tick labels at 0, 1 and 2. A text annotation reads rho equals 0.281, p less than 0.001. A legend titled Location lists Argentina, Australia, Brazil, Canada, China, France, European Union, G20, Germany, Indonesia, India, Italy, Japan, Mexico, Republic of Korea, Russian Federation, Saudi Arabia, South Africa, Turkey, United Kingdom, United States of America and Year. A separate legend titled Year lists 1990, 1995, 2000, 2005, 2010, 2015 and 2020. Points form many dotted sequences across Socio-Demographic Index values from about 0.35 to 0.90. The fitted curve rises from lower Socio-Demographic Index values to a peak around the mid range and then declines toward higher Socio-Demographic Index values and a shaded band surrounds the fitted curve. Several trajectories occupy the middle of the plot around age standardized mortality rate values near 1, while one trajectory at higher Socio-Demographic Index values near 0.8 to 0.9 reaches above the y-axis tick label 2 and then descends. B) Scatter plot with the same layout, legends and fitted curve style, relating Socio-Demographic Index to 1990 to 2023 age standardized DALY rate per 100,000. The x-axis label is Socio-Demographic Index, with tick labels at 0.4, 0.5, 0.6, 0.7, 0.8 and 0.9. The y-axis label is 1990 to 2023 age standardized DALY rate per 100,000, with tick labels at 0, 20, 40 and 60. A text annotation reads rho equals 0.214, p less than 0.001. Points again form multiple dotted trajectories across Socio-Demographic Index values from about 0.35 to 0.90. The fitted curve rises to a mid range peak and then declines at higher Socio-Demographic Index values, with a shaded band around it. Many trajectories cluster between the y-axis tick labels 20 and 40 and one trajectory at higher Socio-Demographic Index values near 0.8 to 0.9 reaches above the y-axis tick label 60 and then descends.

Spearman’s correlation analysis between SDI and burden of female breast cancer attributable to HFPG in China and G20 countries, 1990–2023. (A) ASMR; (B) ASDR. ASMR, age-standardized mortality rate.

Abbreviations: ASDR, age-standardized DALY rate; DALY, disability-adjusted life year.

Decomposition Analysis

Figure 6 and Supplementary Figure S3 identified population expansion and population ageing as key positive drivers of female breast cancer burden linked to HFPG across G20 countries. The epidemiological transition, by contrast, generally exerted a burden-alleviating effect. The contributions of individual drivers varied substantially across countries, and the G20 experienced a substantial net increase in disease burden driven by its large population base. Compared with the G20, China derived larger reductions in burden from epidemiological improvements and smaller increases in burden due to population growth and ageing. Consequently, the net increase in its disease burden was far lower than that of the overall G20.

Figure 6.

Two stacked horizontal bar charts showing decomposed changes in deaths and DALYs for China and G20. A) Stacked horizontal bar chart titled, Deaths. The vertical axis label is, Country or Region, with categories G20 and China. The horizontal axis label is, Value, with tick labels 0, 5,000, 10,000 and 15,000. Legend text reads, Varname, with entries Aging, Epidemiological change, Population and Total net change. For G20, the Epidemiological change segment extends left of 0 to approximately negative 2,000. The Population segment extends rightward from 0 to approximately 12,000. The Aging segment extends further rightward from approximately 12,000 to approximately 18,000. The Total net change marker is located near 16,000 on the Value axis. For China, the Epidemiological change segment extends left of 0 to approximately negative 2,000. The Population segment extends rightward from 0 to approximately 2,000. The Aging segment extends further rightward from approximately 2,000 to approximately 4,000. The Total net change marker is located near 2,500 on the Value axis. B) Stacked horizontal bar chart titled, DALYs. The vertical axis label is, Country or Region, with categories G20 and China. The horizontal axis label is, Value, with tick labels negative 100,000, 0, 100,000, 200,000, 300,000 and 400,000. Legend text reads, Varname, with entries Aging, Epidemiological change, Population and Total net change. For G20, the Epidemiological change segment extends left of 0 to approximately negative 40,000. The Population segment extends rightward from 0 to approximately 330,000. The Aging segment extends further rightward from approximately 330,000 to approximately 450,000. The Total net change marker is located near 410,000 on the Value axis. For China, the Epidemiological change segment extends left of 0 to approximately negative 60,000. The Population segment extends rightward from 0 to approximately 90,000. The Aging segment extends further rightward from approximately 90,000 to approximately 120,000. The Total net change marker is located near 50,000 on the Value axis.

Decomposition analysis of female breast cancer attributable to HFPG in China and the G20. The black dots denote the total net change in deaths and DALYs, calculated as the sum of the three decomposed components.

Abbreviations: DALY, disability-adjusted life year.

BAPC Model Projections

Predictive analysis included 10 representative G20 countries: Brazil, China, India, Indonesia, Japan, Mexico, Russia, Saudi Arabia, South Africa, and the USA. We used the BAPC model to forecast 15-year trends in female breast cancer burden attributable to HFPG. Overall, future disease burden trajectories varied substantially across these countries. According to projections of ASMR and ASDR, only Russia and Mexico exhibited modest downward trends in standardized burden metrics, whereas all other countries witnessed increases of varying magnitudes. South Africa and Saudi Arabia exhibited pronounced burden growth, with increases far exceeding those of other included nations; by contrast, China saw only a mild elevation and retained a relatively low level of standardized risk. In terms of absolute burden, the number of related deaths and DALYs were projected to keep rising over the next 15 years across all 10 countries. India showed the most remarkable expansion: its death toll was projected to rise from 6133 in 2023 to 16,874 in 2038 (a 1.75-fold increase), with DALYs increasing from 190,144 to 632,659 (a 2.33-fold rise), positioning India as the country with the highest long-term burden of HFPG-related female breast cancer. Driven by its large population base, China sustained a high absolute burden. For South Africa and Saudi Arabia, persistently high per-capita risks of death and disability contributed to sharp increases in mortality cases and DALYs (Figure 7 and Supplementary Table S2).

Figure 7.

Four plots showing predicted female breast cancer burden trends in ten G20 countries over time. A) Stacked bar chart of Number of Deaths by Year and Location. Horizontal axis label: Year, with years shown from 1990 through 2040. Vertical axis label: Number of Deaths, with tick labels at 0, 10000, 20000, 30000 and 40000. Legend title: Location. Legend entries: Brazil, China, India, Indonesia, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, United States of America. A vertical dashed line is drawn at Year 2023. The stacked total increases from about 10000 at 1990 to slightly above 40000 by 2040. India and China form the largest stacked portions across the series, with other locations forming smaller stacked portions. B) Stacked bar chart of Number of DALYs by Year and Location. Horizontal axis label: Year, with years shown from 1990 through 2040. Vertical axis label: Number of DALYs, with tick labels at 0, 400000, 800000 and 1200000. Legend title: Location. Legend entries: Brazil, China, India, Indonesia, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, United States of America. A vertical dashed line is drawn at Year 2023. The stacked total increases from about 300000 at 1990 to above 1200000 by 2040. India and China form the largest stacked portions across the series, with other locations forming smaller stacked portions. C) Multi line time series of ASMR per 100000 by Year and Location, split into Observed and Predicted. Horizontal axis label: Year, spanning 1990 to 2040 with labeled ticks at 1990, 2000, 2010, 2020, 2030 and 2040. Vertical axis label: ASMR per 100000, with labeled ticks at 1, 2 and 3. A vertical dashed line marks Year 2023. Legend title: Location. Legend entries: Brazil, China, India, Indonesia, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, United States of America. Legend title: Period, with entries Observed and Predicted, where Observed is drawn as solid lines and Predicted is drawn as dotted lines. In the Observed period, country lines lie roughly between about 0.4 and about 2.0. In the Predicted period, multiple dotted lines rise; one dotted line rises above 3 by 2040, another rises to about 2.6 by 2040 and several others end between about 0.6 and about 1.8 by 2040. D) Multi line time series of ASDR per 100000 by Year and Location, split into Observed and Predicted. Horizontal axis label: Year, spanning 1990 to 2040 with labeled ticks at 1990, 2000, 2010, 2020, 2030 and 2040. Vertical axis label: ASDR per 100000, with labeled ticks at 50, 100 and 150. A vertical dashed line marks Year 2023. Legend title: Location. Legend entries: Brazil, China, India, Indonesia, Japan, Mexico, Russian Federation, Saudi Arabia, South Africa, United States of America. Legend title: Period, with entries Observed and Predicted, where Observed is drawn as solid lines and Predicted is drawn as dotted lines. In the Observed period, most solid lines lie roughly between about 10 and about 55, with one reaching about the mid 50s near 2023. In the Predicted period, several dotted lines increase; one rises above 150 by 2040, another rises to about 70 to 80 by 2040 and several others end between about 20 and about 60 by 2040.

Predicted burden trends of female breast cancer attributable to HFPG in G20 countries, 2024–2038. (A) Number of deaths; (B) Number of DALYs; (C) Number of ASMR; (D) Number of ASDR.

Abbreviations: ASMR, age-standardized mortality rate; ASDR, age-standardized DALY rate; DALY, disability-adjusted life year.

Discussion

Drawing upon the GBD 2023 dataset, this study systematically characterised temporal patterns and medium-to-long-term epidemiological trends of female breast cancer burden attributable to HFPG in China and G20 countries from 1990 to 2023. Across China and the G20, absolute burden continued to rise, while age-standardised burden declined overall, with a discernible rebound between 2020 and 2023. Burden profiles varied substantially across G20 countries. Over an extended period, China maintained relatively low age-standardised burden levels compared with other G20 countries. Spearman’s correlation analysis revealed an inverted-U-shaped association between the SDI and both ASMR and ASDR for HFPG-attributable breast cancer across G20 countries. Our 15-year BAPC projections indicate that burden is likely to increase further in most G20 countries, including China, with a gradual concentration of burden among older populations.

Existing evidence has shown that hyperglycaemia among non-diabetic individuals increases the risk of incident breast cancer.33 One large-scale cohort study reported higher mortality risk for patients with breast cancer and type 2 diabetes, with mortality risk increasing alongside rising blood glucose concentrations.34 Accumulating evidence indicates that tumor initiation and progression are rarely driven by a single molecular abnormality; instead, they stem from the combined effects of multilayered alterations.35 This raises the question of how hyperglycaemia drives breast cancer onset, progression, and clinical prognosis. Recent comprehensive studies have shown that HFPG promotes breast cancer initiation, tumour progression, and poor patient outcomes through multi-layered biological pathways. At the metabolic signalling level, HFPG induces insulin resistance and compensatory hyperinsulinaemia, upregulates insulin-like growth factor-1 (IGF-1), and persistently activates the PI3K/Akt/mTOR pathway and the Ras/Raf/MEK/ERK signalling cascade to accelerate mammary epithelial cell proliferation. Crosstalk between hyperglycaemia and sex hormones such as oestrogen may exert synergistic effects on tumour progression, which has been proposed as one sex-specific mechanism that could partly explain the high prevalence of HFPG-related breast cancer among women.36 Sustained hyperglycaemia induces sustained activation of NF-κB, stimulates excessive secretion of pro-inflammatory factors, and promotes accumulation of advanced glycation end products (AGEs), thereby increasing the risk of genetic mutations.37 Recent cutting-edge molecular studies further confirm that hyperglycaemia selectively upregulates two oncogenes (FIBCD1 and PFKFB3) as well as the non-coding RNA miR-467. These molecules collectively enhance the invasive and metastatic potential of breast tumours.38–40 Hyperglycaemia-induced glycation cross-linking of collagen stiffens the extracellular matrix and further accelerates tumour progression.41 Within the tumour microenvironment, HFPG promotes excessive endogenous oestrogen secretion and CD8+T-cell exhaustion, which mediates immune evasion by cancer cells.42 Sustained glucose supply enhances aerobic glycolysis in tumour cells, impairs DNA repair, and induces resistance to chemotherapy and endocrine therapy.43–45 It should be noted that these biological mechanisms provide biological plausibility for the association between HFPG and breast cancer. However, this ecological study cannot establish causal links between HFPG and breast cancer, nor quantify the contribution of these pathways to the observed disease burden.

Our study demonstrates that the absolute burden of HFPG-attributable female breast cancer continues to rise across G20 countries. This finding aligns with prior analyses based on GBD 2021 and accords with the broader epidemiological pattern of growing burdens for both hyperglycaemia and breast cancer worldwide since 1990.8,20,46 Age-stratified analyses reveal that mortality and DALY burdens increase with advancing age in the G20. We hypothesise that this pattern arises from longer cumulative exposure to high fasting plasma glucose and the widespread prevalence of breast cancer risk factors among older women. Extended life expectancy also enables more women to survive into age groups at high risk of breast cancer; when combined with the tumour-promoting effects of sustained hyperglycaemia, these factors jointly drive increases in absolute disease burden.10,47,48 Notably, age-standardised burdens across the G20 show an overall downward trend, signalling reductions in relative population risk after adjustment for population age structure. This favourable shift may stem from expanded breast cancer screening, improved treatment regimens, advances in endocrine and chemotherapeutic agents, and the roll-out of programmes for metabolic risk factor control in some countries.6,49,50 This trend diverges from global estimates reported in earlier GBD 2021 studies, a discrepancy we attribute to differences in study populations, GBD data revisions and modelling adjustments.46 Of particular note, Joinpoint modelling identified rebounds in ASMR and ASDR between 2020 and 2023 for China and the G20. We speculate that these rebounds may relate to disrupted screening services, shifts in lifestyle behaviours and delayed clinical care during the COVID-19 pandemic.16,51

Our results revealed marked heterogeneity in temporal trends for the burden of female breast cancer attributable to HFPG across G20 countries. Such cross-country disparities in disease burden mirror the evolving global epidemiological landscape of cancer, and are consistent with the findings from the Global Burden of Disease study by Zhang et al46 In recent years, global cancer burden has diverged markedly by socioeconomic development level. While low- and middle-income economies have exhibited sustained rises in this burden, high-income nations show gradual stabilisation or declines. Socioeconomic disparities are a core driver of the uneven global distribution of cancer burden.52 The inverted U-shaped association between SDI and age-standardised disease burden is one of the core findings of this study. We hypothesise that, during the transition from low to moderate SDI, rising burden may be linked to shifts in dietary patterns, sedentary lifestyles, delayed childbearing, and a growing proportion of postmenopausal women. In parallel, inadequate coverage of screening for hyperglycaemia and breast cancer, alongside fragile chronic disease management systems in low-to-middle SDI settings, further amplifies disease burden. By contrast, the decline in burden among high-SDI economies may be attributable to improved health literacy, widespread access to hyperglycaemia and breast cancer screening, the uptake of novel therapeutics and advanced diagnostic tools, and supportive health insurance policies.12,53–57 Prior global analyses have reported an inverted V-shaped association between age-standardised rates of HFPG-attributable breast cancer and SDI, consistent with the inverted U-shaped trend observed among G20 countries in our study.12 Importantly, this non-linear association is derived exclusively from the G20 sample. Given the restricted SDI range of G20 countries, with no very-low-income economies included, this pattern cannot be generalised to all countries.

Over the study period, we observed that China has maintained relatively low age-standardised burden. This temporal pattern accords with previous GBD-based analyses of breast cancer burden attributable to metabolic risk factors among Chinese women.58 The observation may be explained by the higher proportion of premenopausal breast cancer in Chinese women, among whom the tumour-promoting effect of HFPG is weaker than among postmenopausal women, together with a comparatively lower population-level exposure to sustained high fasting plasma glucose.59,60 Furthermore, China has developed a nationwide network of opportunistic fasting glucose screening and long-term follow-up care for people living with diabetes across urban and rural settings.61 This infrastructure may reduce prolonged cumulative HFPG exposure and help sustain this relatively low exposure level. For breast cancer control, organised population-based screening programmes have been scaled up in China since 2009.62,63 Given the high prevalence of dense breasts among local women, ultrasound is prioritised as the primary screening modality. Free from ionizing radiation, affordable, and suitable for repeat short-interval assessment, ultrasound facilitates detection of early-stage lesions and may partly reduce mortality and DALY rates for HFPG-attributable breast cancer. It is important to emphasise that a low age-standardised rate does not equate to a low public health burden. Driven by its large population size, China still bears a substantial absolute number of deaths and DALYs related to HFPG-attributable breast cancer. This burden is at risk of rising in future amid population ageing, urbanization and rising prevalence of metabolic risk factors. The Healthy China 2030 Outline prioritises expanded access to early cancer detection and treatment, alongside primary prevention and standardised management of chronic conditions including disorders of glucose metabolism.22 This policy framework provides direction to curb HFPG prevalence and strengthen breast cancer screening programmes in China.

APC modelling further disentangles the age, period and cohort drivers underlying these between-group burden disparities. Intergroup differences in age effects align with the biological risk profile of HFPG: HFPG confers a stronger breast cancer risk among postmenopausal women, and the relatively lower summary exposure to HFPG among older women in China together explain why the rise in attributable mortality risk after age 55 is markedly slower than that seen across the G20.59,60 The inverted V-shaped distribution of age-specific DALY rates in China suggests potential public health gains from glucose intervention in middle-aged and older adults and early diagnosis and treatment of breast cancer among older women.58 Period effects identify 2008 as a critical inflection point; thereafter, burden declined faster in China than the G20 average, and this temporal shift broadly coincides with the roll-out of primary-care-based hyperglycaemia management and the national rural cervical and breast cancer screening programme.64,65 Cohort effects show progressively reduced HFPG-attributable mortality risk among Chinese women born after 1949, signalling favourable shifts in long-term cumulative metabolic exposure within these generations. Nevertheless, rising prevalence of obesity and HFPG among contemporary young women may create future burden risk.58 A negative net drift indicates an overall downward trend in this attributable burden, while modest increases in burden within older age groups confirm that population ageing may continue to drive up absolute burden. This finding reinforces the notion that a low age-standardised burden does not equate to reduced public health pressure. Importantly, owing to the linear dependency among age, period and birth cohort, APC models cannot fully separate these three effects. Interpretations derived from APC analyses should therefore be made with caution.66

BAPC model projections suggest that the burden of HFPG-attributable female breast cancer will likely rise over the next 15 years across most G20 countries, including China. To mitigate this upward trend, we propose targeted public health recommendations. Integrated prevention of disorders of glucose metabolism and breast cancer should be prioritised: opportunistic fasting plasma glucose screening can be incorporated into routine women’s health checks, with standardised interventions delivered for screen-detected prediabetes, to reduce population-level HFPG exposure and reduce attributable risk via primary healthcare networks.61 Stratified breast cancer screening strategies should be adopted, with screening modalities selected according to local breast cancer epidemiology and a focus on high-risk women with hyperglycaemia, to improve survival through earlier diagnosis.62 Tumour biomarker testing may bridge translational discoveries and clinical practice, facilitating biomarker-guided breast cancer screening and individualised patient management.67 Wearable devices enabling continuous glucose monitoring offer technical support for population-level glucose screening and routine metabolic care, representing a promising avenue for future non-communicable disease surveillance.68 Integrated metabolic–oncology comorbidity management represents an innovative direction for prevention, fostering cross-speciality collaboration between endocrinology and breast cancer clinical teams to explore whether glycaemic control confers prognostic benefits in breast cancer at the population level. Our finding that China has maintained a relatively low HFPG-attributable breast cancer burden within the G20 may offer insights for other middle-SDI nations undergoing socioeconomic transition. Nonetheless, since this study does not compare the effectiveness of national intervention policies, we cannot confirm that China’s prevention strategies are directly transferable. Substantial heterogeneity in burden across G20 countries means that resource allocation for control programmes must be tailored to each country’s development status, demographic profile and burden patterns. Sustained health promotion encouraging healthy diets and physical activity is also needed to lower long-term metabolic risks among young women. Importantly, these recommendations are derived from ecological population-level associations. Further prospective studies remain necessary to verify whether glycaemic control, biomarker-based screening and other proposed measures can effectively reduce HFPG-attributable breast cancer burden.

Compared with previous GBD analyses, this study offers incremental value by using the GBD 2023 dataset and focusing specifically on the burden of HFPG-attributable female breast cancer, thereby complementing the available evidence linking metabolic risk factors and breast cancer burden. However, this study has several notable limitations. First, the dataset lacked data on breast cancer histological subtypes, which hindered stratified burden assessment by tumour subtype. HFPG exposure was defined as fasting glucose values outside the TMREL range of 4.9–5.3 mmol/L, we did not distinguish the separate disease burden contributions of subclinical hyperglycaemia and overt diabetes. Second, All analyses were based on aggregated estimates from the GBD study. Uncertainty inherent to GBD estimates arises from underlying data sources, modelling assumptions, and measurement error. Variation in data quality across countries may introduce bias in cross-country comparisons. Third, as a secondary ecological analysis based on the GBD 2023 dataset, this study only quantifies the population burden of HFPG-attributable female breast cancer and cannot independently establish a causal association between the two. Fourth, the APC model only decomposes temporal trends in HFPG-attributable breast cancer burden. Its estimated period and cohort effects represent mixed signals shaped by multiple co-occurring factors, and, compounded by the model’s inherent non-identifiability, these effect estimates cannot be interpreted as the independent effect of HFPG on breast cancer; nor can they support direct inference about associations between individual-level HFPG exposure and breast cancer risk. Finally, our short-term and medium-term projections using the BAPC model were done only for representative G20 countries, rather than for the G20 as a whole. Forecasts were based on fixed assumptions regarding population growth, lifestyle patterns, and prevalence of metabolic risk factors. Large-scale public health interventions or substantial population-wide changes in lifestyle could therefore lead to real-world burden trends that differ substantially from the projected results.

Conclusion

Over the past 30-plus years, the absolute HFPG-attributable burden of female breast cancer has risen steadily in China and G20 countries, while age-standardised burden has generally declined, with only a modest rebound from 2020 to 2023. Population growth and ageing are the primary drivers underlying increases in absolute burden. Model-based projections suggest that this burden will likely rise further in most G20 countries, including China, over the next 15 years. Marked burden heterogeneity within the G20 underscores the need for context-specific prevention and control strategies tailored to each nation’s demographic, socioeconomic and healthcare conditions. The updated cross-national burden estimates and medium-to-long-term projections from this study can inform integrated planning for hyperglycaemia and breast cancer, and offer public health insights for regions facing concurrent epidemics of these two conditions.

Acknowledgments

Our sincere thanks go to the GBD team, which generously provides free permissions for database access and relevant file downloading.

Ethics Declarations

This study received ethics approval from the Ethics Committee of Zhangzhou Affiliated Hospital of Fujian Medical University (approval number: 2026LWB357).

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

Zhixing Kuang contributed to this study as a member of the GBD collaborative group. Jinzhu Zheng and Shaoxing Chen are designated co-first authors of the present manuscript. All authors declare that there exist no competing interests relevant to this work.

References

  • 1.Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286-287:18–19. doi: 10.1016/j.cancergen.2024.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sung H, Filho AM, Laversanne M, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026;76(4):e70090. doi: 10.3322/caac.70090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mao Y, Chu X, Xie F, et al. Estimates and projections of the global economic cost of breast cancers from 2021 to 2050. Front Endocrinol. 2025;16:1692619. doi: 10.3389/fendo.2025.1692619 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.WHO Regional Office for Europe. Better than screening: with WHO’s help Ukraine chose a cost-efficient policy to prevent breast cancer. WHO Europe. 2021. Available from: https://www.who.int/europe/news/item/08-03-2021-better-than-screening-with-who-s-help-ukraine-chose-a-cost-efficient-policy-to-prevent-breast-cancer. Accessed July 23, 2026. [Google Scholar]
  • 5.Espina C, Ritchie D, Riboli E, et al. European code against cancer 5th edition: 14 ways you can help prevent cancer. Lancet Reg Health Eur. 2026;63:101592. doi: 10.1016/j.lanepe.2026.101592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Bhangdia K, May ML, Kocarnik JM, et al; 2023 Breast Cancer Collaborators. Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023. Lancet Oncol. 2026;27(3):302–326. doi: 10.1016/S1470-2045(25)00730-2 [DOI] [PubMed] [Google Scholar]
  • 7.GBD. 2023 disease and injury and risk factor collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023. A systematic analysis for the global burden of disease study 2023. Lancet. 2025;406(10513):1873–1922. doi: 10.1016/S0140-6736(25)01637-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rooney MR, He JH, Salpea P, et al. Global and regional prediabetes prevalence: updates for 2024 and projections for 2050. Diabetes Care. 2025;48(11):e142–e144. doi: 10.2337/DC25-1640 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ong KL, Stafford LK, McLaughlin SA, et al; GBD. 2021 diabetes collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. Lancet. 2023;402(10397):203–234. doi: 10.1016/S0140-6736(23)01301-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Saroosh R, Ahmad N, Israr B, Arif S, Itrat N, Ahmad AMR. Navigating the nexus of type 2 diabetes mellitus and breast cancer: a comprehensive review of co-occurrence. Front Oncol. 2025;15:1624896. doi: 10.3389/fonc.2025.1624896 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhang A, Zhu X, Li Z, et al. Type 2 diabetes, glycemic traits and overall cancer risk: a large-scale prospective cohort study. Cancer Med. 2026;15(5):e71929. doi: 10.1002/cam4.71929 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhang J, He J, Lu Y, Lan T. Global disease burden of breast cancer attributable to high fasting plasma glucose: a comprehensive analysis from the global burden of disease study. Front Endocrinol. 2025;16:1498207. doi: 10.3389/fendo.2025.1498207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Shi H, Song Z, Chen Y, Liu S, Song Y. The global burden of female breast cancer attributable to high fasting plasma glucose: a comprehensive analysis of the GBD database from 1990 to 2023. PLoS One. 2026;21(10):e0359268. doi: 10.1371/journal.pone.0359268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bhangdia K, May ML, Kocarnik JM, et al; GBD. Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023. Lancet Oncol. 2026;27(3):302–326. [DOI] [PubMed] [Google Scholar]
  • 15.International Monetary Fund. G20 report on Strong, sustainable, balanced, and inclusive growth. Available from: https://www.imf.org/-/media/files/research/imf-and-g20/2024/g20-report-2024-on-strong-sustainable-balanced-and-inclusive-growth.pdf. Accessed July 26, 2026.
  • 16.Taylan O, Alkabaa AS, Yılmaz MT. Impact of COVID-19 on G20 countries: analysis of economic recession using data mining approaches. Financ Innov. 2022;8(1):81. doi: 10.1186/s40854-022-00385-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Li ML, Tang RS, Wang N, et al. Burden of women’s cancers in the group of twenty (G20) from 1990 to 2023: epidemiological trends and impact from fertility, quality of care, and survival. Mil Med Res. 2026;13(1):100026. doi: 10.1016/j.mmr.2026.100026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Akashi H, Ishizuka A, Lee S, Irie M, Oketani H, Akashi R. The role of the G20 economies in global health. Glob Health Med. 2019;1(1):11–15. doi: 10.35772/ghm.2019.01008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wang N, Wang Y, Lv Q, et al. Global burden of disease attributable to high fasting plasma glucose from 1990 to 2021: a spatiotemporal analysis of global burden of disease 2021. Front Cardiovasc Med. 2026;13:1679255. doi: 10.3389/fcvm.2026.1679255 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Force LM, Kocarnik JM, May ML, et al; GBD. 2023 cancer collaborators. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the global burden of disease study 2023. Lancet. 2025;406(10512):1565–1586. doi: 10.1016/S0140-6736(25)01635-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4(1):47–53. doi: 10.1016/j.jncc.2024.01.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Chen P, Li F, Harmer P. Healthy China, 2030: moving from blueprint to action with a new focus on public health. Lancet Public Health. 2019;4(9):e447. doi: 10.1016/S2468-2667(19)30160-4 [DOI] [PubMed] [Google Scholar]
  • 23.Naghavi M, Kyu HH, A B, et al; GBD. 2023 causes of death collaborators. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023. A systematic analysis for the global burden of disease study 2023. Lancet. 2025;406(10513):1811–1872. doi: 10.1016/S0140-6736(25)01917-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Foreman KJ, Lozano R, Lopez AD, Murray CJ. Modeling causes of death: an integrated approach using CODEm. Popul Health Metr. 2012;10(1):1. doi: 10.1186/1478-7954-10-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Schumacher AE, Zheng P, Barber RM, et al; GBD. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the global burden of disease study 2023. Lancet. 2025;406(10513):1731–1810. doi: 10.1016/S0140-6736(25)01330-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Irimata KE, Bastian BA, Clarke TC, Curtin SC, Badwe R, Rui P. Guidance for selecting Model options in the National Cancer institute Joinpoint regression software. Vital Health Stat 1. 2022;194:1–22. [PubMed] [Google Scholar]
  • 27.Jia M, He E, Sun W, et al. Hepatoblastoma regional trends: dynamic SDI & joinpoint regression analysis. BMC Cancer. 2025;25(1):1148. doi: 10.1186/s12885-025-14566-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Luo L, Hodges JS. The age-period-cohort-interaction Model for describing and investigating inter-cohort deviations and intra-cohort Life-course dynamics. Sociol Methods Res. 2022;51(3):1164–1210. doi: 10.1177/0049124119882451 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarker Prev. 2014;23(11):2296–2302. doi: 10.1158/1055-9965.EPI-14-0300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Das Gupta P. Standardization and decomposition of rates from cross-classified data. Genus. 1994;50(3–4):171–196. [PubMed] [Google Scholar]
  • 31.Riebler A, Held L. Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biom J. 2017;59(3):531–549. doi: 10.1002/bimj.201500263 [DOI] [PubMed] [Google Scholar]
  • 32.Knoll M, Furkel J, Debus J, Abdollahi A, Karch A, Stock C. An R package for an integrated evaluation of statistical approaches to cancer incidence projection. BMC Med Res Methodol. 2020;20(1):257. doi: 10.1186/s12874-020-01133-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Holm JB, Bruun JM, Christiansen P, et al. HbA1c levels and breast cancer prognosis in women without diabetes. BMC Cancer. 2025;25(1):790. doi: 10.1186/s12885-025-14121-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Parsons K, Yin H, Yu OHY, Khosrow-Khavar F, Azoulay L. The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer. Breast Cancer Res Treat. 2026;216(1):3. doi: 10.1007/s10549-026-07913-9 [DOI] [PubMed] [Google Scholar]
  • 35.Ubaid S, Kushwaha R, Kashif M, Singh V. Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration. Cancer Genet. 2025;298-299:44–62. doi: 10.1016/j.cancergen.2025.08.010 [DOI] [PubMed] [Google Scholar]
  • 36.Jiang Z, Zhou Y, Ma M, Huang M, Wang X. Unraveling diabetes Mellitus-Driven Tumorigenesis: from pathophysiological mechanisms, therapeutic drugs to tailor-made nanosystems. Int J Nanomed. 2026;21:584898. doi: 10.2147/IJN.S584898 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs. Cells. 2022;11(8):1312. doi: 10.3390/cells11081312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Tan B, Liu Y, Chen Q, et al. Diabetes is causally associated with increased breast cancer mortality by inducing FIBCD1 to activate MCM5-mediated cell cycle arrest via modulating H3K27ac. Cell Death Dis. 2025;16(1):546. doi: 10.1038/s41419-025-07849-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cheng X, Jia X, Wang C, et al. Hyperglycemia induces PFKFB3 overexpression and promotes malignant phenotype of breast cancer through RAS/MAPK activation. World J Surg Oncol. 2023;21(1):112. doi: 10.1186/s12957-023-02990-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gajeton J, Krukovets I, Muppala S, Verbovetskiy D, Zhang J, Stenina-Adognravi O. Hyperglycemia-induced miR-467 drives tumor inflammation and growth in breast cancer. Cancers. 2021;13(6):1346. doi: 10.3390/cancers13061346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Wang W, Hapach LA, Griggs L, et al. Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening. Sci Adv. 2022;8(46):eabo1673. doi: 10.1126/sciadv.abo1673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ennis CS, Llevenes P, Qiu Y, Dries R, Denis GV. The crosstalk within the breast tumor microenvironment in type ii diabetes: implications for cancer disparities. Front Endocrinol. 2022;13:1044670. doi: 10.3389/fendo.2022.1044670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Panigrahi G, Candia J, Dorsey TH, et al. Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency. JCI Insight. 2023;8(23):e170105. doi: 10.1172/jci.insight.170105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Viedma-Rodríguez AR, Martínez-Hernández MG, Flores-López LA, et al. High glucose promotes cisplatin chemoresistance in MDA-MB-231 breast cancer derived cells through changes in gene expression and multiple signaling pathways. Biomed Rep. 2025;23(6):1–15. doi: 10.3892/br.2025.2064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Qiu J, Zheng Q, Meng X. Hyperglycemia and chemoresistance in breast cancer: from cellular mechanisms to treatment response. Front Oncol. 2021;11:628359. doi: 10.3389/fonc.2021.628359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Jiang D, Ma S, Wu Y, et al. Global burden of female breast cancer attributable to high fasting plasma glucose from 1990 to 2021 and projections to 2046: an analysis for the global burden of disease study 2021. Diabetes Metab Res Rev. 2025;41(5):e70063. doi: 10.1002/dmrr.70063 [DOI] [PubMed] [Google Scholar]
  • 47.Li G, Yin M, Fan Z, Qu F. Correlation between fasting blood glucose level and risk of breast cancer in women: a single-center, prospective cohort study. Front Oncol. 2024;14:1359839. doi: 10.3389/fonc.2024.1359839 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Front Public Health. 2025;13:1622954. doi: 10.3389/fpubh.2025.1622954 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6(6):229–239. doi: 10.1186/bcr932 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Coles CE, Earl H, Anderson BO, et al. The lancet breast cancer commission. Lancet. 2024;403(10439):1895–1950. doi: 10.1016/S0140-6736(24)00747-5 [DOI] [PubMed] [Google Scholar]
  • 51.Adachi K, Kimura F, Takahashi H, et al. Delayed diagnosis and prognostic impact of breast cancer during the COVID-19 Pandemic. Clin Breast Cancer. 2023;23(3):265–271. doi: 10.1016/j.clbc.2023.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Bizuayehu HM, Ahmed KY, Kibret GD, et al. Global disparities of cancer and its projected burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi: 10.1001/jamanetworkopen.2024.43198 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Sha R, Kong XM, Li XY, Wang YB. Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the global burden of disease study 2021. Biomark Res. 2024;12(1):87. doi: 10.1186/s40364-024-00631-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Yuan M, Zhu Y, Ren Y, et al. Global burden and attributable risk factors of breast cancer in young women: historical trends from 1990 to 2019 and forecasts to 2030 by sociodemographic index regions and countries. J Glob Health. 2024;14:04142. doi: 10.7189/jogh.14.04142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Fiolet T, Srour B, Sellem L, et al. Consumption of ultra-processed foods and cancer risk: results from NutriNet-santé prospective cohort. BMJ. 2018;360:k322. doi: 10.1136/bmj.k322 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Yin X, Zhang T, Zhang Y, Man J, Yang X, Lu M. The global, regional, and national disease burden of breast cancer attributable to low physical activity from 1990 to 2019: an analysis of the global burden of disease study 2019. Int J Behav Nutr Phys Act. 2022;19(1):42. doi: 10.1186/s12966-022-01283-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2024;74(3):229–263. doi: 10.3322/caac.21834 [DOI] [PubMed] [Google Scholar]
  • 58.Zhang LZ, Sun QC, Luan HH, et al. Historical trends of breast cancer burden attributable to metabolic factors among Chinese women, 1990–2019: a population-based epidemiological study. Thorac Cancer. 2024;15(16):1279–1286. doi: 10.1111/1759-7714.15316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Xu H, Xu B. Epidemiology, early detection, and management of breast cancer in China: a comprehensive review. Chin J Cancer Res. 2025;37(6):882–899. doi: 10.21147/j.issn.1000-9604.2025.06.02 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin nutr. 2007;86(3):s823–s835. doi: 10.1093/ajcn/86.3.823S [DOI] [PubMed] [Google Scholar]
  • 61.Yan L, Ji N, Xu J, et al. Evaluating behavioral risk factor interventions for hypertensive and diabetic patient management in the National Basic Public health Service programs from 2009. China CDC Wkly. 2022;4(19):411–416. doi: 10.46234/ccdcw2022.093 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Song QK, Wang XL, Zhou XN, et al. Breast cancer challenges and screening in China: lessons from current registry data and population screening studies. Oncologist. 2015;20(7):773–779. doi: 10.1634/theoncologist.2014-0351 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Shen S, Zhou Y, Xu Y, et al. A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women. Br J Cancer. 2015;112(6):998–1004. doi: 10.1038/bjc.2015.33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Yao J, Wang H, Yin J, et al. Factors associated with the utilization of community-based diabetes management care: a cross-sectional study in Shandong Province, China. BMC Health Serv Res. 2020;20(1):407. doi: 10.1186/s12913-020-05292-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Xia C, Basu P, Kramer BS, et al. Cancer screening in China: a steep road from evidence to implementation. Lancet Public Health. 2023;8(12):e996–e1005. doi: 10.1016/S2468-2667(23)00186-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Clayton D, Schifflers E. Models for temporal variation in cancer rates. ii: age–period–cohort models. Stat Med. 1987;6(4):469–481. doi: 10.1002/sim.4780060406 [DOI] [PubMed] [Google Scholar]
  • 67.Liu H, Karsidag I, Golin R, Wu G. Bridging discovery and treatment: cancer biomarker. Cancers. 2025;17(22):3720. doi: 10.3390/cancers17223720 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Adepoju VA, Jamil S, Biswas MS, Chowdhury AA. Wearable technology in the management of chronic diseases: a growing concern. Chronic Dis Transl Med. 2025;11(2):117–121. doi: 10.1002/cdt3.156 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from International Journal of Women's Health are provided here courtesy of Dove Press

RESOURCES